Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.1.409

In Vivo Evaluation of Curcumin-loaded Nanoparticles in a A549 Xenograft Mice Model  

Yin, Hai-Tao (Department of Radiotherapy, the Central Hospital of Xuzhou, Affiliated Hospital of Southeast University)
Zhang, De-Geng (Department of Oncology, Jiangsu Taizhou People's Hospital)
Wu, Xiao-Li (Department of Women Health Care, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University)
Huang, Xin-En (Department of Chemotherapy, JiangSu Cancer Hospital and Research Institute)
Chen, Gang (Department of Oncology, the Affiliated Jiangning Hospital of Nanjing Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.1, 2013 , pp. 409-412 More about this Journal
Abstract
Curcumin (Cum) has been reported to have potential chemo-preventive and chemotherapeutic activity through influencing various processes, inducing cell cycle arrest, differentiation and apoptosis in a series of cancers. However, the poor solubility of Cum limits its further applications in the treatment of cancer. We have previously reported Cum-loaded nanoparticles (Cum-NPs) prepared with amphilic methoxy poly(ethylene glycol)-polycaprolactone (mPEG-PCL) block copolymers. The current study demonstrated superior antitumor efficacy of Cum-NPs over free Cum in the treatment of lung cancer. In vivo evaluation further demonstrated superior anticancer effects of Cum-NPs by delaying tumor growth compared to free Cum in an established A549 transplanted mice model. Moreover, Cum-NPs showed little toxicity to normal tissues including bone marrow, liver and kidney at a therapeutic dose. These results suggest that Cum-NPs are effective to inhibit the growth of human lung cancer with little toxicity to normal tissues, and could provide a clinically useful therapeutic regimen. They thus merit more research to evaluate the feasibility of clinical application.
Keywords
Curcumin; nanoparticle; in vivo; lung cancer; antitumor efficacy;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Zhang LQ, Huang XE, Wang J, (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
2 Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.   DOI   ScienceOn
3 Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
4 Yu B, Tai HC, Xue W, et al (2010). Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol, 27, 286-98.   DOI   ScienceOn
5 Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.   DOI   ScienceOn
6 Rothdiener M, Beuttler J, Messerschmidt SK, et al (2010). Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol Biol, 624, 295-308.   DOI   ScienceOn
7 Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403.   DOI   ScienceOn
8 Surh YJ, Chun KS, Cha HH, et al (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res, 1, 480-1.
9 Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
10 Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
11 Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
12 Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.   DOI   ScienceOn
13 Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 23, 363-98.
14 Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
15 Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
16 Yin H, Zhang H, Liu B (In press). Superior Anticancer Efficacy of Curcumin-Loaded Nanoparticles Against Lung Cancer. Acta Biochim Biophys Sin.
17 Aggarwal BB, Sung B (2009). Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci, 30, 85-94.   DOI   ScienceOn
18 Hossain M, Banik NL, Ray SK (2012). Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int, 61, 1102-13.   DOI   ScienceOn
19 Hosta-Rigau L, Olmedo I, Arbiol J, et al (2010). Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem, 21, 1070-8.   DOI   ScienceOn
20 Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
21 Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.   DOI   ScienceOn
22 Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.   DOI   ScienceOn
23 Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.Asian Pac J Cancer Prev, 11, 1059-62.
24 Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
25 Li CG, Huang XE, Li Y, et al (2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pac J Cancer Prev, 12, 487-90.
26 Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
27 Liu S, Yang H, Wan L, et al (2013). Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide magainin II. Cancer Biother Radiopharm, Jan 3. [Epub ahead of print]
28 Liu Wei, Li Suyi, Huang Xinen, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.   DOI   ScienceOn
29 Pan MH, Lin-Shiau SY, Lin JK (2000). Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IKappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol, 60, 1665-76.   DOI   ScienceOn
30 Phillips JM, Clark C, Herman-Ferdinandez L, et al (2011). Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. Otolaryngol Head Neck Surg, 145, 58-63.   DOI
31 Rocks N, Bekaert S, Coia I, et al (2012). Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer, 107, 1083-92.   DOI   ScienceOn
32 Almansour NM, Pirogova E, Coloe PJ, et al (2012). Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study. Future Med Chem, 4, 1553-65.   DOI   ScienceOn
33 Cutler CS, Chanda N, Shukla R, et al (2013). Nanoparticles and phage display selected peptides for imaging and therapy of cancer. Recent Results Cancer Res, 194, 133-47.   DOI
34 Duvoix A, Blasius R, Delhalle S, et al (2005). Chemopreventive and therapeutic effects of curcumin. Cancer Lett, 223, 181-90.   DOI   ScienceOn
35 EI-Azab M, Hishe H, Moustofa Y, et a1 (2011). Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol, 652, 7-14.   DOI   ScienceOn
36 Franzen S (2011). A comparison of pettide and folate receptor targeting of cancer cells: from single agent to nanoparticle. Expert Opin Drug Deliv, 8, 281-98.   DOI   ScienceOn
37 Ganta S, Amiji M (2009). Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm, 6, 928-39.   DOI   ScienceOn
38 Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
39 Guo H, Lu J, Hathaway H, et al (2011). Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides. Bioconjug Chem, 22, 1682-9.   DOI   ScienceOn
40 Gong P, Huang XE, Chen CY, et al (2012). Comparison of complications of peripherally inserted central catheters with ultrasound guidance or conventional methods in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.   DOI   ScienceOn